99B0 Stock Overview
QuiaPEG Pharmaceuticals Holding AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
QuiaPEG Pharmaceuticals Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.0058 |
| 52 Week High | kr0.14 |
| 52 Week Low | kr0.0001 |
| Beta | 0.92 |
| 1 Month Change | 18.37% |
| 3 Month Change | -18.31% |
| 1 Year Change | -71.00% |
| 3 Year Change | -99.94% |
| 5 Year Change | n/a |
| Change since IPO | -99.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| 99B0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.5% | 1.8% | 1.1% |
| 1Y | -71.0% | -23.5% | 1.9% |
Return vs Industry: 99B0 underperformed the German Biotechs industry which returned -24.4% over the past year.
Return vs Market: 99B0 underperformed the German Market which returned 2% over the past year.
Price Volatility
| 99B0 volatility | |
|---|---|
| 99B0 Average Weekly Movement | 26.4% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 99B0's share price has been volatile over the past 3 months.
Volatility Over Time: 99B0's weekly volatility has decreased from 1276% to 26% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 3 | Marcus Bosson | www.quiapeg.com |
QuiaPEG Pharmaceuticals Holding AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as well as antibody-drug conjugates being developed using the company’s Uni-Qleaver technology-platform.
QuiaPEG Pharmaceuticals Holding AB (publ) Fundamentals Summary
| 99B0 fundamental statistics | |
|---|---|
| Market cap | €520.75k |
| Earnings (TTM) | -€1.41m |
| Revenue (TTM) | €373.31k |
1.4x
P/S Ratio-0.4x
P/E RatioIs 99B0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 99B0 income statement (TTM) | |
|---|---|
| Revenue | kr4.37m |
| Cost of Revenue | kr2.20m |
| Gross Profit | kr2.17m |
| Other Expenses | kr18.69m |
| Earnings | -kr16.52m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 49.63% |
| Net Profit Margin | -377.75% |
| Debt/Equity Ratio | 135.1% |
How did 99B0 perform over the long term?
See historical performance and comparison